Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases; the COLOPEC 2 randomized multicentre trial by Bastiaenen, Vivian P. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
STUDY PROTOCOL Open Access
Second and third look laparoscopy in pT4
colon cancer patients for early detection of
peritoneal metastases; the COLOPEC 2
randomized multicentre trial
Vivian P. Bastiaenen1* , Charlotte E. L. Klaver1, Niels F. M. Kok2, Johannes H. W. de Wilt3, Ignace H. J. T. de Hingh4,
Arend G. J. Aalbers2, Djamila Boerma5, Andre J. A. Bremers3, Jacobus W. A. Burger4, Eino B. van Duyn6,
Pauline Evers7, Wilhelmina M. U. van Grevenstein8, Patrick H. J. Hemmer9, Eva V. E. Madsen10,
Petur Snaebjornsson11, Jurriaan B. Tuynman12, Marinus J. Wiezer5, Marcel G. W. Dijkgraaf13,
Jarmila D. W. van der Bilt1,14 and Pieter J. Tanis1*
Abstract
Background: Approximately 20–30% of patients with pT4 colon cancer develop metachronous peritoneal metastases
(PM). Due to restricted accuracy of imaging modalities and absence of early symptoms, PM are often detected at a stage
in which only a quarter of patients are eligible for curative intent treatment. Preliminary findings of the COLOPEC trial
(NCT02231086) revealed that PM were already detected during surgical re-exploration within two months after primary
resection in 9% of patients with pT4 colon cancer. Therefore, second look diagnostic laparoscopy (DLS) to detect PM at a
subclinical stage may be considered an essential component of early follow-up in these patients, although this needs
confirmation in a larger patient cohort. Furthermore, a third look DLS after a negative second look DLS might be
beneficial for detection of PM occurring at a later stage.
Methods: The aim of this study is to determine the yield of second look DLS and added value of third look DLS after
negative second look DLS in detecting occult PM in pT4N0-2M0 colon cancer patients after completion of primary
treatment. Patients will undergo an abdominal CT at 6 months postoperative, followed by a second look DLS
within 1 month if no PM or other metastases not amenable for local treatment are detected. Patients without
PM will subsequently be randomized between routine follow-up including 18 months abdominal CT, or an
experimental arm with a third look DLS provided that PM or incurable metastases are absent at the 18
months abdominal CT. Primary endpoint is the proportion of PM detected after a negative second look DLS
and will be determined at 20 months postoperative.
Discussion: Second look DLS is supposed to result in 10% occult PM, and third look DLS after negative
second look DLS is expected to detect an additional 10% of PM compared to routine follow-up alone in
patients with pT4 colon cancer. Detection of PM at an early stage will likely increase the proportion of
patients eligible for curative intent treatment and subsequently improve survival, given the uniformly reported
direct association between the extent of peritoneal disease and survival.
Trial registration: ClinicalTrials.gov: NCT03413254, January 2018.
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Background
Colorectal cancer (CRC) is the third most common can-
cer worldwide, with an estimated incidence of over 1.8
million in 2018 [1]. A common site of recurrence in pa-
tients with CRC is the peritoneum, which is the sole site
of recurrence in up to 25% [2]. Peritoneal dissemination
of colorectal origin largely depends on clinical stage and
histological subtype and was formerly considered a ter-
minal condition with dismal prognosis. Median survival
is only about 5 months if untreated and ranges between
5.2 and 12.6 months if treated with 5-fluorouracil and
leucovorin-based systemic chemotherapy [3–5]. Modern
systemic therapy regimens have significantly improved
patient outcomes. Patients with isolated, resectable peri-
toneal metastases (PM) have median survival of up to
24months with oxaliplatin/irinotecan-containing combi-
nations with or without biological agents [6–9]. How-
ever, systemic treatment results in lower survival benefit
in PM as compared with non-peritoneal metastases, and
long-term survival remains limited with 5-year survival
probability of only 13% [6, 9, 10].
Currently, the only curative option for PM is cytore-
ductive surgery (CRS) followed by hyperthermic intra-
peritoneal chemotherapy (HIPEC). The purpose of this
multimodal approach is to surgically remove all visible
peritoneal tumour deposits and to eradicate microscopic
residual disease with intraperitoneal administration of
heated chemotherapy [11]. Previous studies have shown
that CRS/HIPEC improves survival in comparison with
systemic chemotherapy alone [3, 6, 12–14]. In a system-
atic review including nineteen cohort studies and thir-
teen comparative studies published between 2010 and
2015, the weighted median overall survival after treat-
ment with CRS/HIPEC was 31.6 months and the 5-year
survival rate ranged between 22 and 51% [8].
The efficacy of CRS/HIPEC highly depends on the ex-
tent of peritoneal involvement, which is often assessed
with the peritoneal cancer index (PCI) as proposed by
Jacquet and Sugarbaker [3, 15–22]. Patients with a low
PCI (1–5) have reported median survival of up to 81
months and 5-year survival rates exceeding 70%,
whereas only about 10% of patients with extensive PM
(PCI ≥16) are alive at 5 years postoperative [23, 24]. Be-
sides a survival benefit, limited extent of peritoneal dis-
ease is also correlated with lower postoperative
morbidity following CRS [15, 17, 19, 25]. Furthermore,
in patients with a low PCI, less extensive surgery is re-
quired to achieve completeness of cytoreduction, which
is another important prognostic factor for survival [3, 6,
15–19, 25–27].
The availability of an effective therapy, and the fact
that CRS/HIPEC yields better survival rates and lower
postoperative morbidity when the extent of peritoneal
disease is more limited, underline the importance of
detection and treatment of PM in its initial stages. How-
ever, early PM cannot be detected with clinical or radio-
logical methods due to the absence of symptoms and
restricted accuracy of imaging modalities. Sensitivity of
CT for the detection of PM ranges from 60 to 79%, but
drops below 30% in case of peritoneal lesions smaller
than 5 mm [28]. As a result, PM are often detected at a
stage in which only about 20–25% of patients can be
treated with CRS/HIPEC. Therefore, new diagnostic
strategies are urgently required to detect PM at a
clinically occult stage, which will probably result in a
higher percentage of patients eligible for intentional
curative treatment. This is supposed to translate into
better survival, considering the direct association
between PCI and survival.
Currently, the only way to diagnose minimal PM is by
re-exploration of the abdominal cavity during second
look surgery. The concept of second look surgery was
first described by Wangensteen in 1948 and is based on
the systematic use of planned reoperation in asymp-
tomatic patients who are theoretically at risk for de-
veloping recurrent or metastatic disease, despite
initial curative resection of the primary tumour [29].
Since it is an invasive and costly procedure, second
look surgery should only be proposed to selected pa-
tients at high-risk of developing PM. An advanced
stage of colon cancer has been shown to be an im-
portant risk factor for the development of PM [30,
31]. After curative resection of a pT4 primary tumour,
the risk of developing metachronous PM is approxi-
mately 30% [32].
In 2017, our study group completed the accrual of 204
patients in the COLOPEC randomized controlled trial
(NCT02231086), which investigated the effect of adju-
vant HIPEC preceding routine adjuvant systemic therapy
on the outgrowth of PM after resection of pT4 or perfo-
rated colon cancer [33]. In most patients, adjuvant
HIPEC was applied as a staged procedure 5–8 weeks
after resection of the primary tumour. As part of the
trial, routine diagnostic laparoscopy (DLS) at 18 months
was performed in both arms to determine the effective-
ness of adjuvant HIPEC based on the 18 months periton-
eal metastases free survival (PMFS, primary endpoint).
Results of the primary endpoint are expected at the be-
ginning of 2019. However, PM were already detected
during surgical exploration, which was part of the
planned adjuvant HIPEC procedure, in 9% of patients
(preliminary unpublished data). Based on these findings
and literature, a second look DLS to detect PM when
the disease is still potentially curable by CRS/HIPEC
may be considered an essential component of early
follow-up of pT4 colon cancer patients. This finding
needs confirmation in a larger patient cohort before
implementing this into routine practice. Some patients
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develop metachronous PM at a longer interval (> 12
months) from primary resection, and those patients will
be missed by a second look DLS [34]. For this reason,
there might be benefit of a third look DLS after a nega-
tive second look DLS to detect occult metachronous PM
later on. In the COLOPEC trial, a quarter of detected
PM among both arms of the study were found at 18
months DLS after negative CT (preliminary unpublished
data). These findings will be further explored in the
COLOPEC 2 trial.
Methods/design
This study protocol is written in accordance with the
SPIRIT guidelines [35, 36]. The SPIRIT Checklist is pro-
vided in Additional file 1.
Objectives
The primary objectives of this study are to determine
the yield of second look DLS and the added value of a
third look DLS after a negative second look DLS in pa-
tients who underwent resection of pT4a,bN0-2M0 colon
cancer for the detection of clinically occult PM which
are amenable for curative intent treatment. Main
secondary objectives are to determine the 5-year peri-
toneal metastases free, disease-free and overall survival.
Design
This is a prospective multicentre randomized controlled
trial of the Dutch Peritoneal Oncology Group (DPOG)
and Dutch Colorectal Cancer Group (DCCG) with a
two-armed parallel design and 1:1 allocation ratio. This
study started in February 2018 and will be performed in
approximately 30 Dutch hospitals, both HIPEC centres
and non-HIPEC centres. Eligible patients will undergo
an abdominal CT at six months postoperative. For pa-
tients who still have to finish adjuvant systemic chemo-
therapy, a maximum delay of three months will be
allowed for this CT scan. If the CT scan is negative for
peritoneal recurrence or other metastases that are not
curable, a second look DLS will be performed within
one month from this CT scan. Patients without PM dur-
ing the second look DLS will subsequently be random-
ized to routine follow-up including an abdominal CT at
18months followed by third look DLS in the experimen-
tal arm, or routine follow-up including an abdominal
CT at 18months alone in the control arm (Fig. 1). A
maximum delay of one month is allowed for the 18
months CT scan. The third look DLS in the experimen-
tal arm will not be performed in patients with:
 PM found during routine follow-up or on CT-
imaging;
 Non-peritoneal recurrence that would impede
curative intent treatment of PM if detected,
according to the local multidisciplinary team.
Patients in whom PM are found at any time during
follow-up will be treated by CRS/HIPEC or alternative
treatment (palliative systemic therapy or best supportive
care) according to the Dutch guideline and patient
preferences [37].
Study population
Patients who underwent intentional curative resection of
pT4a,bN0-2M0 colon cancer or rectosigmoid cancer
above the peritoneal reflection, with or without adjuvant
systemic chemotherapy, will be considered for inclusion.
In order to be eligible to participate in this study, a
subject must meet all of the following criteria:
 Age between 18 and 80 years;
 Written informed consent.
A potential subject who meets any of the following cri-
teria will be excluded from participation in this study:
 Histological types other than adenocarcinoma,
mucinous adenocarcinoma or signet-ring cell
carcinoma;
 Clinical condition that does not allow for second
look surgery or subsequent treatment of PM if
detected;
 Second look surgery thought not to be technically
possible (i.e. because of extensive abdominal surgery
/ re-interventions).
Enrolment
Eligible patients will be approached for entry into the
study at the first outpatient visit after resection of the
primary tumour. The rationale for the study will be ex-
plained to the patient. A patient information sheet is
provided and patients will be given the opportunity to
ask questions. After a sufficient reflection period, pa-
tients are asked to sign the consent form. Written in-
formed consent is taken by surgeons, surgical registrars
or trained research nurses prior to any study procedures.
When consent has been obtained, the original form is
kept in the study file and a copy is given to the patient.
The study coordinator will register all included patients
in a registration module built with ALEA (FormsVision).
Every registered patient will be assigned a sequential
subject number consisting of three digits. A notification
of the registration will be sent to the local investigator of
the site where the patient was included. A log of the
assigned subject numbers will be maintained by each
site.
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Fig. 1 Flowchart. CT, computed tomography; DLS, diagnostic laparoscopy; PM, peritoneal metastases
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Standard care between inclusion and randomization
Blood samples to determine carcinoembryonic antigen
(CEA) levels are collected at 3, 6 and 9months postop-
erative. At 6–9months after resection of the primary
tumour with or without adjuvant systemic chemother-
apy, CT imaging of the abdomen is performed in all in-
cluded patients who are in an adequate clinical
condition to undergo DLS. All patients without signs of
PM or non-peritoneal recurrence that would impede
curative treatment of PM if detected on CT will
undergo a second look DLS. The surgical procedure
is described below.
Randomization
Randomization will take place after the second look
DLS. Patients without PM during second look DLS will
be randomized in a 1:1 ratio between routine follow-up
including an abdominal CT at 18 months followed by
third look DLS (experimental arm) and routine
follow-up including an abdominal CT at 18months
alone (control arm). Randomization with permuted
blocks of random sizes will be performed by the study
coordinator using the registration module built with
ALEA (FormsVision). The block sizes will not be dis-
closed to ensure concealment. Stratification factors will
be the surgical approach of the primary tumour resec-
tion (laparoscopy or open), pathological nodal stage (N0
or N1–2), and adjuvant systemic chemotherapy (yes or
no, yes: at least four cycles of capecitabine and oxalipla-
tin (CAPOX) or six cycles of 5-fluorouracil, leucovorin
and oxaliplatin (FOLFOX), allowing dose reduction and
omission of oxaliplatin, no: all other cases) [30, 31]. In
order to prevent caretakers from being influenced by the
assigned follow-up strategy, the randomization outcome
will remain unknown to participants and everyone in-
volved in the patient’s care until the 18 months CT scan
of the abdomen is reported by the radiologist. Once the
radiology report of the abdominal CT is available, a noti-
fication with the assigned allocation is sent to the local
investigator of the site where the patient was included.
Standard care of the control arm
Follow-up following negative second look DLS will be
performed routinely according to the Dutch guideline
[37]. Patients visit the outpatient clinic twice a year dur-
ing the first two to three years and annually thereafter,
until five years postoperative. CEA-levels are determined
at 12, 15, 18, 21, 24, 30, 36, 48 and 60months after pri-
mary resection. Imaging of the liver using ultrasound or
CT is performed at 12, 24, 36, 48 and 60months postop-
erative. At 18 months postoperative, an abdominal CT is
part of the study protocol, but ultrasound of the liver is
allowed for other time intervals during follow-up. Col-
onoscopy is performed at 12 and 48months postopera-
tive. The follow-up schedule is displayed in Table 1.
Standard care of the experimental arm
Follow-up in the experimental arm is similar to the con-
trol arm except for a third look DLS following the ab-
dominal CT at 18months. Third look DLS is not
performed in patients with evidence of disease that is
not curable, or in those already diagnosed with PM in
the preceding period.
Second and third look DLS
Surgeons experienced in performing DLS for the detec-
tion of PM will proctor the procedure in the participat-
ing non-HIPEC centres. After proctoring, surgeons in
the participating non-HIPEC centres are asked to pro-
vide videos from their first three individually performed
cases in order to monitor their skills. The patient is
placed in French position on a bean bag under general
anesthesia. Open introduction of a 10–12mm trocart is
performed outside areas of expected adhesions (i.e.
Palmer’s point) and a CO2 pneumoperitoneum is
created. Additional trocars of 5 mm are placed under
direct vision to allow for adequate adhesiolysis and in-
spection. All regions of the abdominal cavity, including
the local resection site, are systematically and thoroughly
inspected. Adhesiolysis is performed if necessary, and
extent of adhesiolysis should be determined based on an
optimal balance between improved visualization and risk
Table 1 Routine follow-up schedule
TIMEPOINT
months after primary resection
3 6 9 12 15 18 21 24 30 36 48 60
CEA X X X X X X X X X X X X
Abdominal CT X Xa X
Ultrasound / CT liver X X X X X
Colonoscopy X X
Diagnostic laparoscopy X Xa Xb
CEA carcinoembryonic antigen, CT computed tomography
aIn case of delay related to adjuvant systemic chemotherapy
b According to randomization
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of (bowel) damage. Conversion to laparotomy if there is
inadequate exposure during DLS is prohibited, while
this is considered to be too invasive for diagnostic
purposes in this trial setting according to the mem-
bers of the research committee of the DPOG. If ad-
equate exploration of the abdomen appears not to be
possible by laparoscopy, the procedure has to be
stopped. It is only allowed to convert to laparotomy
in case of an intra-operative complication that re-
quires intervention by an open approach. The PCI
score is used to assess the extent of peritoneal disease
if present. Samples from lesions suspicious for PM
are taken and sent to the pathology lab. After inspec-
tion of the entire abdominal cavity, trocars are re-
moved and port sites are closed in standard fashion.
Patients will be treated in an outpatient surgery set-
ting and will be discharged from the hospital if they
meet all discharge criteria.
DLS is associated with a low risk of wound infection
of the trocar sites, bleeding from the abdominal wall or
biopsy sites, and bowel injury related to adhesiolysis.
With an expected number needed to diagnose clinically
occult PM of 10, DLS related morbidity will probably
not outweigh the potential survival benefit related to
higher proportions of curative intent treatment com-
pared to detection at a clinically apparent stage.
Outcomes
Primary study endpoint
The primary endpoint of the study is the proportion of
PM detected after a negative second look DLS. The pri-
mary endpoint will be determined at 20 months.
Secondary study endpoints
Secondary endpoints of the COLOPEC II trial are:
 Incidence of PM at second look DLS and at 20months
after curative resection of the primary tumour,
depending on pT4 subdivision, pathological nodal
stage, histology and receipt of adjuvant chemotherapy;
 Proportion of PM at 20 months after curative
resection of the primary tumour that was detected
with routine follow-up including abdominal CT at
18 months in both arms and with third look DLS in
the experimental arm;
 Proportion of detected PM eligible for CRS + HIPEC
at different follow-up intervals;
 Clinical manifestation of PM within 6 months of the
second look DLS;
 Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) of CT
imaging to detect PM;
 Thirty-day morbidity related to second/third look
DLS;
 Extent of adhesions assessed with the Zühlke score and
need for adhesiolysis at second/third look DLS [38];
 Peritoneal recurrence free survival rate at 5 years;
 In patients with a negative second look DLS;
 In patients with a negative 18 months abdominal
CT who did or did not subsequently undergo
third look DLS.
 Disease-free survival rate at 5 years;
 In patients with a negative second look DLS;
 In patients with a negative 18 months abdominal
CT who did or did not subsequently undergo
third look DLS.
 Overall survival rate at 5 years;
 In patients with a positive second look DLS;
 In patients with a negative second look DLS;
 In patients with a negative CT-abdomen at 18
months who did or did not subsequently undergo
third look DLS.
 Quality of life at 1 year and 2 years (CRC-29; EQ-
5D-5 L).
Sample size calculation
It is expected that 87% of included patients will have
negative second look DLS (Fig. 1). These patients will be
randomized. It is expected that about 5% will be diag-
nosed with irresectable metastases located outside the
peritoneum between 6 and 18months postoperative, and
another 2% will present themselves with clinically mani-
fest PM before the 18 months CT. The abdominal CT at
18months postoperative will presumably identify an-
other 3% true positives (3.06% testing positive; positive
predictive value of CT: 0.98). Hence, it is expected that
PM will be detected in about 5% of patients in the con-
trol arm at 20months. Assuming a negative predictive
value of the 18months CT for PM of 0.89 and assuming
that the third look DLS followed by evaluation by the
pathologist if biopsies were taken will identify all CT
false negatives, it is expected that, overall, PM will be de-
tected in approximately 15% of patients in the experi-
mental arm. This results in an absolute difference of
10%, which is considered to be clinically relevant. If 320
patients (160 per group) with negative second look DLS
are randomized, a Fisher’s exact test for two independent
proportions with a 0.025 one-sided significance level will
have 80% power to detect an absolute difference of 10%
in actual PM at 20 months (about 5% under routine
follow-up and approximately 15% under third look sur-
gery at 18–20 months). Because of an expected dropout
rate of 5%, 338 subjects will be randomized to ensure
that a minimum sample size of 320 patients is obtained.
In order to achieve this number of patients, 338/0.87, or
389 patients should initially be included. The calculation
was based on PASS 2005 software.
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Recruitment
The Dutch ColoRectal Audit (DCRA, former DSCA) re-
vealed that in 2011 approximately 10.500 patients were
diagnosed with colon cancer, of which 14% presented
with a pT4 stage colon carcinoma. Despite the introduc-
tion of bowel cancer screening, this percentage has not
decreased, probably due to better histological diagnosis
of peritoneal penetration related to more awareness of
its clinical consequences. In 2016, more than 1600 pa-
tients (15%) were diagnosed with a pT4 stage colon
tumour. Based on an estimated drop-out of 15% due to
age older than 80 years, the estimated number of eligible
patients for the COLOPEC 2 trial is about 1.350 each
year. During the COLOPEC trial, a wide network of sur-
geons throughout the Netherlands was built and patient
accrual went faster than expected. The COLOPEC 2 trial
will be performed in the same centres as in the COLO-
PEC trial, so the participating centres are familiar with
performing randomized controlled trials and the sur-
geons are aware of the risk of pT4 colon cancer patients
to develop PM. Therefore, it is expected that patient
accrual can be completed in three years.
Data collection and data management
Data collection and data management will be performed
by the Netherlands Comprehensive Cancer Organization
(IKNL). Their experience with continuous data collec-
tion based on high quality electronic case report forms
(eCRFs) guarantees complete and timely recording,
handling and storage of data and documents. All local
and central data managers are registered and the elec-
tronic database (TRIAS) is ISO certified. Data will be
documented in line with ‘Good Clinical Practice (GCP)’
and Dutch legal requirements. Major violations of the
protocol will be recorded.
In all participating hospitals, one surgeon acts as local
investigator who is primarily responsible for practical
execution of the trial in compliance with the study
protocol. The local investigators will be responsible for
accuracy and completeness of data. Data will be regis-
tered in the patient file by the treating physician. In
every hospital, a local data manager of IKNL is respon-
sible for entering the data in the electronic database.
After inclusion, baseline characteristics including patient
and tumour characteristics will be retrieved from pa-
tients’ charts. During the DLS, information about the
surgical procedure will be collected by the surgeon on a
paper case record form. During the 30-day postoperative
period, adverse events will be reviewed and documented.
During routine outpatient clinic visits for oncological
follow-up at 3, 6, 12, 18, 24, 36, 48 and 60 months,
disease recurrence will be checked. Quality of life as-
sessments will be done with the CR-29 questionnaire
and the EQ-5D-5 L health status questionnaire. In
case a subject has withdrawn, the reason for with-
drawal will be documented and no further study as-
sessments will be performed. Subjects whom have
been withdrawn from the study but are still willing to
participate in the routine follow-up will be followed
according to the specifications of the patient. The
schedule for enrolment, interventions and assessments
is summarized in Table 2.
The central data manager of IKNL develops the eCRFs
including range checks for data values, adds participat-
ing hospitals to the database, tests the database, and in-
forms the local datamanagers about how to use the
database. The central datamanager assures the progress
of data collection, will maintain quality of documenta-
tion by local data managers in the eCRF, and clarifies
mistakes where necessary. In case of uncertainties or
questions in the eCRF, additional queries for the local
data managers may be formulated by the central
datamanager.
Data analysis
All analyses described below will be performed in the
newest SPSS-version at the time of analysis. A
p-value below 0.05 will indicate statistical signifi-
cance in case of formal testing of differences
between diagnostic strategies. No correction for mul-
tiple testing will be applied.
Primary study endpoint
Proportions of patients with detected PM following a
negative second look DLS will be reported per diagnostic
strategy, including the 95% confidence intervals. The dif-
ference in proportions between both diagnostic strat-
egies will be tested with the Fisher’s exact test.
Additional analyses by Cochran-Mantel-Haenszel testing
will be performed to account for the stratification vari-
ables. Hardly any missing primary outcome data are ex-
pected, e.g. the nationwide study design allows for study
continuation by patients if they happen to move to an-
other region.
Secondary study endpoints
Incidences of PM at different time points, depending on
pT4 subdivision, pathological nodal stage, histological
type and receipt of adjuvant chemotherapy will be de-
scriptively reported per diagnostic strategy as rates per
100 patients, along with their 95% confidence intervals.
Similar descriptive analyses will be applied to the (i) pro-
portion of PM at 20months after curative resection of
the primary tumour that was detected with routine
follow-up including abdominal CT at 18months in both
arms and with third look DLS in the experimental arm,
(ii) the proportion of detected PM eligible for curative
intent CRS +HIPEC at different follow-up intervals; (iii)
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clinical manifestation of PM within 6 months of second
look DLS. No formal testing of differences between diag-
nostic strategies will be applied to these incidence rates
and proportions, but the derived rate ratios will be re-
ported along with the 95% confidence intervals to ex-
plore how both diagnostic strategies perform in various
subgroups of patients.
Using pathology results or clinical progression as the
reference standard, the sensitivity, specificity, PPV and
NPV of CT for the diagnosis of PM will be calculated
and reported as proportions along with their 95% confi-
dence interval. The 30-day morbidity related to second/
third look DLS will be tabulated as counts by type of
morbidity, allowing patients to contribute to different
types of morbidity. In addition, the distribution of the
number of morbidities per patient will be reported. The
extent of adhesiolysis required at second/third look DLS
will be reported in tabular format as counts for the sec-
ond as well as third look DLS.
Kaplan-Meier survival analyses for patients with nega-
tive second look DLS will be applied to describe the time
till disease recurrence and time till death for each diag-
nostic strategy, censoring patients without disease recur-
rence, respectively still alive at the end of follow-up
(study closure or day of lost-to-follow-up). Differences
between diagnostic strategies in time till disease recur-
rence or time till death will be assessed with the
log-rank test. Similar Kaplan-Meier survival analyses will
be used for patients with a negative abdominal CT at 18
months as well as patients with a positive second look
DLS to describe the time till death.
Generalized linear mixed modelling will be applied to
assess differences in quality of life between both diagnostic
strategies over time. Mixed models are considerably ro-
bust against the presence of missing data.
Monitoring
No data and safety monitoring board (DSMB) will be
assigned, since patients are subjected to an intervention
with a low postoperative morbidity that is already being
performed in routine clinical practice. No interim ana-
lyses will be performed.
Auditing
Independent monitoring of the study progress and study
quality is performed by a qualified monitor of IKNL.
The monitor plan is based on the judgement of the IRB
that study participation is of moderate risk. Monitoring
will be done by exploring the electronic trial database
and performing site visits. Each participating site will be
visited at least once, with repeat visits to sites where per-
formance is a concern. The quality assessment will focus
on the safety, wellbeing and rights of the patients, the
quality of the documented data in the eCRF and their
traceability to source documents and the completeness
of the regulatory binder. Furthermore, the trial monitor
Table 2 Schedule of enrolment, interventions and assessments
CT computed tomography
a In case of delay related to adjuvant systemic chemotherapy
b According to randomization
c Including peritoneal metastases assessment
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checks if the study is executed according to the study
protocol, GCP and the declaration of Helsinki. After
each monitor visit, the trial monitor reports feedback to
the project leader, study coordinator and local
investigator.
Adverse events
All adverse events (AEs) and serious adverse events
(SAEs) reported spontaneously by the subject or ob-
served by the investigator or his staff in the first 30 days
after second/third look DLS will be recorded. The study
coordinator will report all SAEs to the accredited Insti-
tutional Review Board (IRB) that approved the study
protocol. The clinical course of each AE will be followed
until resolution, stabilization or until it has been deter-
mined that study treatment or participation is not the
cause. SAE’s, which are still ongoing at the end of the
study period, must be followed up to determine the
final outcome.
Ethics
The IRB of the Amsterdam UMC, location AMC, has
approved the study protocol (MEC 2017_134,
NL61507.018.17). All amendments will require formal
approval of the IRB prior to implementation. This study
will be conducted according to the principles of the Dec-
laration of Helsinki (Fortaleza, October 2013) and in ac-
cordance with the Medical Research Involving Human
Subjects Act (WMO) and other guidelines, regulations
and Acts. The study was registered at ClinicalTrials.gov
before recruitment of the first participant
(NCT03413254, first posted in January 2018).
Communication about patients will occur with the
assigned study number. The full name and birth date of
the patient will only be recorded on the informed con-
sent form. In order to maintain confidentiality during
and for fifteen years after completion of the study, all
study-related information will be stored using the
assigned study number in a secure and accessible place
and manner. Digital files will be stored on
password-protected computers in password-protected
folders. Only the project leader and study coordinator
have full access to the complete final dataset.
The AMC Medical Research BV has an insurance,
which is in accordance with the legal requirements in
the Netherlands (Article 7 WMO). This insurance pro-
vides cover for damage to research subjects through in-
jury or death caused by the study. The insurance applies
to the damage that becomes apparent during the study
or within 4 years after.
Dissemination
The COLOPEC 2 trial is designed within the research
networks of DPOG and DCCG. The DPOG is a national
multidisciplinary working group with the common goal
of improving the treatment of peritoneal malignancies
by carrying out multidisciplinary scientific research. Pro-
gress and final results of the study will be discussed dur-
ing the regular meetings of both research groups, and
updates will be available on the website. The results of
the COLOPEC 2 trial will be presented at national and
international congresses and submitted for publication
to a peer-reviewed scientific journal.
Discussion
The use of second look surgery for detection of PM in
pT4 colon cancer patients
There is no published trial on routine second look sur-
gery in proven pT4 colon cancer patients. The COLO-
PEC 2 trial has some overlap with a currently recruiting
Italian randomized trial investigating the role of second
look surgery six months postoperatively in mucinous
CRC (NCT01628211). All other ongoing trials are ad-
dressing the role of simultaneous prophylactic HIPEC in
clinical T4 stage colon cancer: the PROMENADE trial
(NCT02974556), and an almost similar Spanish multi-
centre study (NCT02614534). The inclusion criteria of
these trials are essentially different from the COLOPEC
2, because the COLOPEC 2 is based on pathological T4
stage, thereby also including pT4a tumours that are
often missed based on clinical staging. Furthermore, the
COLOPEC 2 will investigate the impact of just DLS and
only CRS/HIPEC if PM are found. Finally the role of
third look laparoscopy has never been investigated. In
the majority of other previously published and ongoing
clinical trials concerning the use of second look surgery
for early detection of PM, the patient group consists of
patients with resected minimal synchronous macro-
scopic PM, synchronous ovarian metastases or perfor-
ation of the primary tumour. In our opinion, local
peritoneal nodules that were resected at the time of pri-
mary surgery and resected ovarian metastases should be
considered as already proven PM instead of risk factors
for developing PM. According to the Dutch guideline,
these patients would not have been treated with systemic
therapy first, but would routinely be treated by upfront
CRS/HIPEC immediately after the diagnosis of local
peritoneal nodules or ovarian metastases.
Selection of patients at high risk of developing PM,
but who were never diagnosed with PM, is another
clinical scenario. Several studies have identified an ad-
vanced tumour stage as an independent risk factor for
the development of PM [30–32, 39]. Except for a
Chinese trial (NCT02179489) including both patients
with proven PM as well as patients at high risk of
developing PM (i.e. pT4 colon cancer and/or tumour
perforation), studies regarding the impact of second look
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surgery in pT4 patients are lacking. Therefore, we think
the COLOPEC 2 trial has a unique trial design, which
essentially differs from previous and ongoing trials in
this field.
Abdominal CT and second look DLS as standard
components of follow-up
CT imaging of the abdomen at 6 and 18months can be
considered a standard diagnostic tool according to the
Dutch guideline, in which CT is recommended instead
of ultrasound of the liver in patients at high risk of de-
veloping recurrence at 6 months interval in the first 2
years and yearly until 5 years postoperatively [37]. The
second look DLS is currently not included in the Dutch
guideline. However, second look surgery is increasingly
applied in patients at high risk of developing PM in- and
out-side trial setting. The preliminary findings of the
COLOPEC trial and the increasing body of literature on
risk of developing PM justify the systematic performance
of second look DLS in this study. The results of this
study will contribute to the evidence on second look
DLS as an essential component in the follow-up of pa-
tients with pT4 colon cancer.
Rationale for design; timing of DLS
According to the Dutch guideline, adjuvant systemic
chemotherapy is indicated after curative intent resection
of all pT4 cancers, both stage II and stage III, and should
start preferably within 8 weeks and seems not beneficial
if started after more than 3months postoperatively [37].
Standard duration of adjuvant chemotherapy is 3 to 6
months. A substantial number of patients with pT4
colon cancer will not receive adjuvant systemic chemo-
therapy, because they experience complications or are
unfit to start adjuvant systemic therapy within 12 weeks
postoperatively [34]. Second look DLS in the 2months
postoperative period as performed in the COLOPEC
trial has the disadvantage of delaying systemic chemo-
therapy. In the COLOPEC 2 trial, this delay cannot be
justified, since only 10% of patients will benefit from the
second look DLS, while the remaining 90% of patients
might harm from the delay. Furthermore, such an early
DLS is not possible in patients with abdominal compli-
cations (i.e. anastomotic leakage, abscess, fascial dehis-
cence), and might also be difficult after uncomplicated
resections because of fresh adhesions, for example after
open multivisceral resection. Finally, one might
hypothesize that patients with rapid disease progression
even before start of chemotherapy or during adjuvant
treatment are probably beyond any curative intent treat-
ment and will therefore not benefit from early detection.
Therefore, DLS between 6 and 10 months postopera-
tively, depending on the delivery and duration of adju-
vant chemotherapy, is regarded the most optimal timing
to detect early development of metachronous PM at a
curable stage. With CT-imaging, approximately 90% of
PM are found within three years after primary resection
[40]. It is expected that these PM can be detected at an
earlier stage using DLS. Based on this assumption, the
timing of the third look DLS between 18 and 20months
postoperative was chosen.
Duration of adjuvant chemotherapy for stage III colon
cancer is currently subject of debate. A collaboration of
six trials including 12.834 patients with stage III colon
cancer showed an absolute difference of only 0.9% in
3-year disease-free survival after 3 months adjuvant
chemotherapy compared to 6 months, while reducing
the risk of neurotoxicity and other adverse events [41].
Changing recommendations in duration of adjuvant
chemotherapy in the Dutch colorectal cancer guideline
might positively influence the timing of second look
DLS in the COLOPEC 2 trial, because this will allow for
an increasing number of patients to be evaluated at 6
months postoperatively, irrespective of receiving adju-
vant chemotherapy.
Costs
There may be concerns about the additional costs re-
lated to the DLS. However, it is expected that these add-
itional costs will weigh against gained life years and
reduced costs of patients in whom PM would have been
detected at a clinically apparent stage if no third look
DLS was performed. These reduced costs will be the re-
sult of less postoperative morbidity and less need of pal-
liative interventions, if PM are more often detected at a
clinically occult stage.
Additional file
Additional file 1: Recommended items to address in a clinical trial
protocol and related documents. (DOCX 49 kb)
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